Chronic Lymphocytic Leukemia (CLL)
96
20
26
41
Key Insights
Highlights
Success Rate
73% trial completion
Published Results
23 trials with published results (24%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.6%
15 terminated out of 96 trials
73.2%
-13.3% vs benchmark
5%
5 trials in Phase 3/4
56%
23 of 41 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 41 completed trials
Clinical Trials (96)
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Expanded Access to Venetoclax
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms